<DOC>
	<DOCNO>NCT00098852</DOCNO>
	<brief_summary>RATIONALE : Drugs rosiglitazone may make tumor cell sensitive radioactive iodine . PURPOSE : This phase II trial study well rosiglitazone work treat patient locoregionally extensive metastatic thyroid cancer .</brief_summary>
	<brief_title>Rosiglitazone Treating Patients With Locoregionally Extensive Metastatic Thyroid Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine complete response patient locoregionally extensive metastatic differentiate thyroid cancer treat rosiglitazone . Secondary - Compare long-term response patient treat drug historical control . - Determine toxicity profile drug patient . - Determine presence/persistence tumor patient treat drug . - Determine quality life patient treated drug . - Determine overall survival patient treated drug . OUTLINE : This pilot study . Patients receive oral rosiglitazone daily week 1-8 . Patients also receive oral liothyronine sodium twice daily week 1-6 preparation radioactive iodine scan . Treatment continue absence disease progression unacceptable toxicity . At week 8 , patient undergo whole body radioactive iodine scan follow treatment dose radioiodine ass radioiodine uptake tumor . Quality life assess baseline end study treatment . Patients follow 2 week , 1 , 4 , 10 month , every 6 month 1 year . PROJECTED ACCRUAL : A total 20-25 patient accrue study .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis differentiate thyroid cancer Locoregionally extensive and/or metastatic disease Inoperable disease Failed prior conventional therapy include total/neartotal thyroidectomy AND radioactive iodine I 131 ablation therapy Elevated thyroglobulin ( Tg ) level ( &gt; 3 ng/mL thyroid hormone OR &gt; 10 ng/mL thyroid hormone ) Tgantibody positive patient eligible despite Tg level Radioactive iodine ( RAI ) scan show therapeutically insignificant ( &lt; 1 % ) RAI uptake thyroid hormone withdrawal Scan perform within past 18 month PATIENT CHARACTERISTICS : Age 18 Performance status Not specify Life expectancy Not specify Hematopoietic Hemoglobin ≥ 10 g/dL WBC ≥ 3,000/mm^3 Platelet count ≥ 50,000/mm^3 Hepatic ALT ≤ 2 time upper limit normal Renal Creatinine ≤ 1.5 mg/dL Cardiovascular No New York Heart Association class III IV cardiac disease Other Not pregnant No nursing within past 3 month Negative pregnancy test Fertile patient must use effective contraception No allergy thiazolidinediones No malignancy except basal cell skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy More 3 month since prior chemotherapy Endocrine therapy See Disease Characteristics No concurrent levothyroxine Radiotherapy See Disease Characteristics No prior cumulative dose radioiodine ≥ 800 mCi Prior adjuvant therapeutic external beam radiotherapy allow Surgery See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>recurrent thyroid cancer</keyword>
	<keyword>stage II follicular thyroid cancer</keyword>
	<keyword>stage IV follicular thyroid cancer</keyword>
	<keyword>stage II papillary thyroid cancer</keyword>
	<keyword>stage IV papillary thyroid cancer</keyword>
</DOC>